Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma

R. Abbate, A. M. Gori, S. Pinto, R. Paniccia, M. Coppo, M. Tramontana, G. G N Serneri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Platelet aggregation in whole blood and platelet-rich plasma (PRP) and thromboxane A2 (TxA2) production in serum were investigated in ten healthy subjects before and at various intervals (1, 3, 8, and 24 hours) after single and repeated (7 days) oral administrations of dipyrone in different dosages (50, 100, 250, 500, and 1,000 mg). A dose-dependent inhibition of platelet aggregation (r = .90; P <0.001) induced by 1.5 mg/L collagen in PRP and of TxA2 production (r = .88; P <0.001) was found three hours after drug administration and progressively decreased after eight and 24 hours. Interestingly, a statistically significant (P <0.001) inhibitory effect of dipyrone on platelet aggregation was also observed in whole blood, but it was consistently lower than that in PRP, suggesting an important interference of white blood cells with platelet functions and with the antiplatelet drug effects. The seven-day treatment, probably increasing or accelerating liver drug metabolization, induced a decrease in the duration of action on platelet aggregation and TxA2 production compared with single administration.

Original languageEnglish
Pages (from-to)853-863
Number of pages11
JournalCurrent Therapeutic Research
Volume45
Issue number5
Publication statusPublished - 1989

Fingerprint

Dipyrone
Platelet-Rich Plasma
Platelet Aggregation
Thromboxane A2
Blood Platelets
Platelet Aggregation Inhibitors
Pharmaceutical Preparations
Oral Administration
Healthy Volunteers
Leukocytes
Collagen
Liver
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Abbate, R., Gori, A. M., Pinto, S., Paniccia, R., Coppo, M., Tramontana, M., & Serneri, G. G. N. (1989). Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma. Current Therapeutic Research, 45(5), 853-863.

Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma. / Abbate, R.; Gori, A. M.; Pinto, S.; Paniccia, R.; Coppo, M.; Tramontana, M.; Serneri, G. G N.

In: Current Therapeutic Research, Vol. 45, No. 5, 1989, p. 853-863.

Research output: Contribution to journalArticle

Abbate, R, Gori, AM, Pinto, S, Paniccia, R, Coppo, M, Tramontana, M & Serneri, GGN 1989, 'Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma', Current Therapeutic Research, vol. 45, no. 5, pp. 853-863.
Abbate R, Gori AM, Pinto S, Paniccia R, Coppo M, Tramontana M et al. Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma. Current Therapeutic Research. 1989;45(5):853-863.
Abbate, R. ; Gori, A. M. ; Pinto, S. ; Paniccia, R. ; Coppo, M. ; Tramontana, M. ; Serneri, G. G N. / Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma. In: Current Therapeutic Research. 1989 ; Vol. 45, No. 5. pp. 853-863.
@article{98059f5adb124f45aa439f536eee2425,
title = "Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma",
abstract = "Platelet aggregation in whole blood and platelet-rich plasma (PRP) and thromboxane A2 (TxA2) production in serum were investigated in ten healthy subjects before and at various intervals (1, 3, 8, and 24 hours) after single and repeated (7 days) oral administrations of dipyrone in different dosages (50, 100, 250, 500, and 1,000 mg). A dose-dependent inhibition of platelet aggregation (r = .90; P <0.001) induced by 1.5 mg/L collagen in PRP and of TxA2 production (r = .88; P <0.001) was found three hours after drug administration and progressively decreased after eight and 24 hours. Interestingly, a statistically significant (P <0.001) inhibitory effect of dipyrone on platelet aggregation was also observed in whole blood, but it was consistently lower than that in PRP, suggesting an important interference of white blood cells with platelet functions and with the antiplatelet drug effects. The seven-day treatment, probably increasing or accelerating liver drug metabolization, induced a decrease in the duration of action on platelet aggregation and TxA2 production compared with single administration.",
author = "R. Abbate and Gori, {A. M.} and S. Pinto and R. Paniccia and M. Coppo and M. Tramontana and Serneri, {G. G N}",
year = "1989",
language = "English",
volume = "45",
pages = "853--863",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Differences in antiaggregating activity of dipyrone in whole blood and in platelet-rich plasma

AU - Abbate, R.

AU - Gori, A. M.

AU - Pinto, S.

AU - Paniccia, R.

AU - Coppo, M.

AU - Tramontana, M.

AU - Serneri, G. G N

PY - 1989

Y1 - 1989

N2 - Platelet aggregation in whole blood and platelet-rich plasma (PRP) and thromboxane A2 (TxA2) production in serum were investigated in ten healthy subjects before and at various intervals (1, 3, 8, and 24 hours) after single and repeated (7 days) oral administrations of dipyrone in different dosages (50, 100, 250, 500, and 1,000 mg). A dose-dependent inhibition of platelet aggregation (r = .90; P <0.001) induced by 1.5 mg/L collagen in PRP and of TxA2 production (r = .88; P <0.001) was found three hours after drug administration and progressively decreased after eight and 24 hours. Interestingly, a statistically significant (P <0.001) inhibitory effect of dipyrone on platelet aggregation was also observed in whole blood, but it was consistently lower than that in PRP, suggesting an important interference of white blood cells with platelet functions and with the antiplatelet drug effects. The seven-day treatment, probably increasing or accelerating liver drug metabolization, induced a decrease in the duration of action on platelet aggregation and TxA2 production compared with single administration.

AB - Platelet aggregation in whole blood and platelet-rich plasma (PRP) and thromboxane A2 (TxA2) production in serum were investigated in ten healthy subjects before and at various intervals (1, 3, 8, and 24 hours) after single and repeated (7 days) oral administrations of dipyrone in different dosages (50, 100, 250, 500, and 1,000 mg). A dose-dependent inhibition of platelet aggregation (r = .90; P <0.001) induced by 1.5 mg/L collagen in PRP and of TxA2 production (r = .88; P <0.001) was found three hours after drug administration and progressively decreased after eight and 24 hours. Interestingly, a statistically significant (P <0.001) inhibitory effect of dipyrone on platelet aggregation was also observed in whole blood, but it was consistently lower than that in PRP, suggesting an important interference of white blood cells with platelet functions and with the antiplatelet drug effects. The seven-day treatment, probably increasing or accelerating liver drug metabolization, induced a decrease in the duration of action on platelet aggregation and TxA2 production compared with single administration.

UR - http://www.scopus.com/inward/record.url?scp=0024374898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024374898&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 853

EP - 863

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 5

ER -